These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 33610004)

  • 1. Efficacy and safety of apatinib in recurrent/metastatic nasopharyngeal carcinoma: A pilot study.
    Huang L; Zhang X; Bai Y; Chua KLM; Xie Y; Shu X; Long B; Fan C; Lim DWT; Tan SH; Wee JTS; Wang Y; Wu Y; Chua MLK
    Oral Oncol; 2021 Apr; 115():105222. PubMed ID: 33610004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apatinib for the treatment of metastatic or locoregionally recurrent nasopharyngeal carcinoma after failure of chemotherapy: A multicenter, single-arm, prospective phase 2 study.
    Ruan X; Liang JH; Pan Y; Cai R; Zhang RJ; He Z; Yang X; Niu Z; Jiang W
    Cancer; 2021 Sep; 127(17):3163-3171. PubMed ID: 34043812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety of apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis.
    Lin H; Weng X; Wu X; Wu L
    Transl Cancer Res; 2022 Jun; 11(6):1770-1780. PubMed ID: 35836539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial.
    Tang LQ; Li XY; Li ZM; Liu ZG; Lin MZ; Zhou H; Yu QW; Zhou J; Zhao C; Chen ZB; Wang XC; Peng JY; Chen QY; Fang WF; Yang YP; Zhang B; Xia LP; Hu PL; Hu WH; Li YJ; Mai HQ; Cai XY
    BMC Med; 2023 Mar; 21(1):94. PubMed ID: 36927541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Single-Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer.
    Chen X; Qiu T; Zhu Y; Sun J; Li P; Wang B; Lin P; Cai X; Han X; Zhao F; Shu Y; Chang L; Jiang H; Gu Y
    Oncologist; 2019 Jul; 24(7):883-e407. PubMed ID: 30877190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Efficacy And Safety Of Apatinib Treatment For Patients With Metastatic Or Recurrent Cervical Cancer: A Retrospective Study.
    Yu J; Xu Z; Li A; Zhang J; Wang Y; Zhao H; Zhu H
    Drug Des Devel Ther; 2019; 13():3419-3424. PubMed ID: 31576114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study.
    Li L; Kong F; Zhang L; Li X; Fu X; Wang X; Wu J; Zhang F; Ren L; Zhang M
    Invest New Drugs; 2020 Dec; 38(6):1847-1853. PubMed ID: 32363427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Pilot Study of Apatinib as Third-Line Treatment in Patients With Heavily Treated Metastatic Colorectal Cancer.
    Liang L; Wang L; Zhu P; Xia Y; Qiao Y; Wu J; Zhuang W; Fei J; Wen Y; Jiang X
    Clin Colorectal Cancer; 2018 Sep; 17(3):e443-e449. PubMed ID: 29576426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of apatinib in patients with recurrent epithelial ovarian cancer.
    Miao M; Deng G; Luo S; Zhou J; Chen L; Yang J; He J; Li J; Yao J; Tan S; Tang J
    Gynecol Oncol; 2018 Feb; 148(2):286-290. PubMed ID: 29248198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer.
    Hu X; Cao J; Hu W; Wu C; Pan Y; Cai L; Tong Z; Wang S; Li J; Wang Z; Wang B; Chen X; Yu H
    BMC Cancer; 2014 Nov; 14():820. PubMed ID: 25376790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Efficacy and Safety of Apatinib for the Treatment of Patients with Metastatic, Recurrent Cervical Cancer after Failure of Radiotherapy and First-Line Chemotherapy: A Prospective Study.
    Xia X; Jiang W; Qi W; Hong B; Zhao W
    Oncol Res Treat; 2020; 43(12):649-655. PubMed ID: 33045704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis.
    Liu JY; Zhu BR; Wang YD; Sun X
    Int J Clin Oncol; 2020 Jun; 25(6):1195-1205. PubMed ID: 32215805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: An observational study.
    Zhu B; Li J; Xie Q; Diao L; Gai L; Yang W
    Cancer Biol Ther; 2018 Mar; 19(3):198-204. PubMed ID: 29261005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of apatinib in patients with recurrent or metastatic head and neck squamous cell carcinoma: a retrospective multi-center study.
    Liu Z; Zheng Z; Dong L; Guo X; Jia X; Wang J; Meng L; Cui X; Jiang X
    Sci Rep; 2022 Oct; 12(1):18327. PubMed ID: 36316341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.
    Hu X; Zhang J; Xu B; Jiang Z; Ragaz J; Tong Z; Zhang Q; Wang X; Feng J; Pang D; Fan M; Li J; Wang B; Wang Z; Zhang Q; Sun S; Liao C
    Int J Cancer; 2014 Oct; 135(8):1961-9. PubMed ID: 24604288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.
    Li J; Qin S; Xu J; Xiong J; Wu C; Bai Y; Liu W; Tong J; Liu Y; Xu R; Wang Z; Wang Q; Ouyang X; Yang Y; Ba Y; Liang J; Lin X; Luo D; Zheng R; Wang X; Sun G; Wang L; Zheng L; Guo H; Wu J; Xu N; Yang J; Zhang H; Cheng Y; Wang N; Chen L; Fan Z; Sun P; Yu H
    J Clin Oncol; 2016 May; 34(13):1448-54. PubMed ID: 26884585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apatinib Monotherapy for Chemotherapy-Refractory Metastatic Colorectal Cancer: A Multi-centre, Single-Arm, Prospective Study.
    Wang F; Yuan X; Jia J; Bi X; Zhou Z; Zhou Q; Li X; Luo C; Deng M; Yi L; Li Y; Lu J; Su W; Chen H; Zhu Y; Wang S
    Sci Rep; 2020 Apr; 10(1):6058. PubMed ID: 32269247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, safety and predictive indicators of apatinib after multilines treatment in advanced nonsquamous nonsmall cell lung cancer: Apatinib treatment in nonsquamous NSCLC.
    Wu D; Liang L; Nie L; Nie J; Dai L; Hu W; Zhang J; Chen X; Han J; Ma X; Tian G; Han S; Long J; Wang Y; Zhang Z; Xin T; Fang J
    Asia Pac J Clin Oncol; 2018 Dec; 14(6):446-452. PubMed ID: 29573236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Observation of the therapeutic effect of apatinib in advanced platinum-resistant recurrent epithelial ovarian cancer.
    Pan Z; Luo Z; He H; Chen Y; Zhao B; Yang Z; Li L
    J Ovarian Res; 2023 Feb; 16(1):44. PubMed ID: 36823642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apatinib in treating patients with recurrent or metastatic nasopharyngeal carcinoma who had failed prior platinum-based chemotherapy.
    Tao CJ; Zhang P; Zhou L; Hu QY; Chen XZ
    Transl Cancer Res; 2020 Oct; 9(10):6392-6401. PubMed ID: 35117247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.